According to the latest research by Future Market Insights (FMI), the tattoo removal lasers market closed in on US$ 179 million in 2018. The revenue growth of tattoo removal lasers market has been estimated at a promising rate over the course of coming years. While over 7 in 10 patients prefer aesthetic clinics for the procedure of tattoo removal lasers, market value share of tattoo studios is likely to expand in coming years, as per FMI’s analysis.

Tattoo removal lasers have been incorporating the latest laser technologies specific to tattoo removal procedures. Constant developments in the tattoo removal lasers landscape, increase in product penetration across different regions, and increasing government support for R&D of innovative tattoo removal lasers will remain key demand determinants in tattoo removal lasers market.

Several new technologies have been contributing to the revenue growth of tattoo removal lasers market. However, picosecond tattoo removal lasers are extremely expensive. A combination of wavelengths has been in high demand for tattoo removal. For instance, according to a research study conducted on five patients by the Laser Health Academy, better clearance was achieved with a combination of 1,550 nm non-ablative fractional laser+YAG laser as compared to other tattoo removal lasers. The combination of YAG+YAG also resulted in shorter recovery time.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-2013

According to research studies conducted on tattoo removal lasers, a combination of QS Nd: YAG (1064 nm) and CO2 lasers for tattoo removal also resulted in a significantly high improvement on the combination side for Indian skin. Combination of tattoo removal techniques is being perceived as more effective than only Q-S tattoo removal lasers, as the former reduces the need for multiple sessions.

Moreover, combination tattoo removal lasers have not only reduced the number of sessions required, but also cut costs and reduced adverse effects such as hyper-pigmentation, long-going inflammatory responses, and bulla formation. Extensive research on the efficacy of these combination tattoo removal lasers are warranted, specifically considering the high patient demand for tattoo clearance. Thus, the high demand for combination tattoo removal lasers has consistently driven the tattoo removal lasers market.

However, tattoo removal lasers work differently on different skin types, which may involve multiple adverse effects. Tattoo removal lasers that involve Q-switched also require eye protection for the prevention of retinal damage. Q-switched ruby tattoo removal lasers are linked with high clearance rates but are also contradictory because of the high incidence of prolonged hypopigmentation. Such adverse effects of tattoo removal lasers will remain are expected to hamper the growth of the tattoo removal lasers market during the forecast period.

Preview Analysis Global Tattoo Removal Lasers Market Segmentation  By Product Type (Q-Switched Laser, Picosecond Laser, Combination Laser); By End Use (Aesthetic Clinics, Tattoo Studios): https://www.futuremarketinsights.com/reports/tattoo-removal-lasers-market

The tattoo removal lasers market report tracks some of the key companies operating in the tattoo removal lasers market, which include Hologic Inc. (Cynosure), Shanghai Fosun Pharmaceutical（Group）Co., Ltd. (Alma Lasers), Cutera,  Syneron® Medical Ltd., Fotona d.o.o., LUTRONIC, Lumenis, El.En. S.p.A. (Asclepion Laser Technologies GmbH), and Lynton Lasers.

Some of the commonplace complications that result post tattoo removal lasers treatment include prolonged erythema, hyperpigmentation, hypertrophic scar formation, and disseminated infection. On the other side, complications associated with fractional lasers include transient pigmentary changes, mild fibrosis, and hypopigmentation. Though most of the adverse effects associated with tattoo removal lasers can be cured within a short span of time, some of them may lead to serious complications in terms of skin texture and pigmentation.

The growth of weight loss and obesity management market is attributed to the rising epidemic of obesity across the globe. According to the latest research by Future Market Insights (FMI), the global weight loss and obesity management market is anticipated to reach a valuation of over US$ 4.9 Bn, by the end of 2028. The weight loss and obesity management market is expected to expand at a steady CAGR of 5.2%, over the forecast period of 2018-2028.

Developing Regions More Prone to Obesity & Other Comorbidities

Increasing number of cases of obesity and related comorbidities will lead to the growing adoption of drugs and devices for weight loss and obesity management, which will further fuel the growth of the global weight loss and obesity management market during the forecast period.

The weight loss and obesity management market is majorly driven by the rising prevalence of obesity. The rising epidemic of obesity presents a major challenge to disease prevention across the globe. It is estimated that by 2030, 38% of the world’s adult population will be overweight and around 20% will be obese. This obesity epidemic is more prevalent in the Middle East and the Asia Pacific regions where food import is quite high. Weight loss and obesity management are helpful in the treatment of highly critical obesity and comorbidities associated with it, such as diabetes, asthma, sleep apnea, and hypertension, etc.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-411

Increasing health consciousness is also cited as an important factor boosting the revenue growth of the global weight loss and obesity management market. Sizeable consumer population in developed regional markets will particularly continue to generate high demand for weight loss and obesity management practices, according to the report. Millennial and Generation-X consumers are gradually adopting advanced aesthetic services, including weight loss and obesity management, thereby creating adequate opportunities for manufacturers of weight loss and obesity management drugs and devices.

Key Vendors Targeting Extension of Product Portfolio

Leading companies operating in weight loss and obesity management market are majorly focusing on strengthening their product portfolio. Product line extensions help companies to launch newer products with unique features for specific indications. This results in an increased market share of companies in the highly competitive weight loss and obesity management market. In response to increasing demand from various healthcare professionals to effectively treat obesity with minimum long-term side effects, manufacturers are focusing on developing innovative and specific products.

Product innovation is expected to boost revenue and volume growth of the weight loss and obesity management market during the forecast period. For instance, an additional FDA patents approval for VIVUS, Inc.’s Qsymia, for the covering compositions of Qsymia and covering methods for effecting weight loss using Qsymia (phentermine and topiramate).

Preview Analysis Global Weight Loss and Obesity Management Market Segmented By Product type (drugs, devices); By distribution sales (institutional sales, retail sales): https://www.futuremarketinsights.com/reports/weight-loss-and-obesity-management-market

However, the high cost involved in research and development of obesity drugs is a great challenge for the growth of the weight loss and obesity management market. Additionally, long gestation time required for research and developmental activities as well as the need for a number of essential clinical trials to test drugs adds up to significant expenditure. The limitations posed by high development cost of anti-obesity drugs might hinder the growth of the global weight loss and obesity management market. Moreover, the high cost of surgical procedures, such as gastric bypass surgery, adjustable gastric banding, gastric sleeve surgery and gastric balloon treatment, may also affect the growth of the global weight loss and obesity management market adversely.

The global weight loss and obesity management market is estimated based on product type, and distribution sales. Based on product type, the weight loss and obesity management market has been segmented into drugs and devices.

Drugs product type segment is further segmented into GLP-1 receptor agonists, lipase inhibitors, serotonin receptor agonist, a combination drug, and others. Devices product type segment is further segmented into liposuction devices, bariatric stapling devices, gastric band, gastric balloon systems, gastric emptying systems, and gastric electrical stimulation systems.

Devices segment is expected to hold maximum market share in the global weight loss and obesity management market. Based on distribution sales, the weight loss and obesity management market has been segmented into institutional sales and retail sales. In terms of revenue, institutional sales dominated the global weight loss and obesity management market in 2017.

The approximately US$ 25 Bn market for benign prostatic hyperplasia prostate treatment is likely to expand at 4.6% CAGR during 2018-2028, according to a recent research report of Future Market Insights (FMI). The report has envisaged steady growth prospects for the revenue of global benign prostatic hyperplasia prostate treatment market through 2028.

The World Population Prospects’ data (2017) projected that the number of individuals aged 60 years and above will double by 2050, and triple by 2100. With such a high pace estimated for the growth of population aged 60 years and above, it is more likely that the prevalence of aging related health conditions will also increase at a considerable pace in the years to come. A high prevalence rate of benign prostatic hyperplasia (BPH) in men, the demand for improved and more effective treatment options continues to increase at a high rate.

Alpha-blockers & Drugs for Lower UTIs Remain Pivotal in Benign Prostatic Hyperplasia Prostate Treatment

The drug treatment has been vital in treating benign prostatic hyperplasia conditions and lower UTIs, which has been attributed to widespread availability of drug-based benign prostatic hyperplasia prostate treatment. This factor, in particular, will play an instrumental role in driving the growth of the benign prostatic hyperplasia prostate treatment market during the forecast period. Drugs will remain the first choice of treatment for benign prostatic hyperplasia.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1664

Benign prostatic hyperplasia increases the risk of other disorders as well. The most common disorder caused due to benign prostatic hyperplasia is lower UTI (urinary tract infection) for which, Alpha-blockers constitute the first line of treatment. However, other drugs are also available in the market, which offer relief from the benign prostatic hyperplasia symptoms. Other drugs include alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs.

Demand for Benign Prostatic Hyperplasia Prostate Treatment Higher in Developed Regions, Patient Pool Expanding Steadily in Developing Markets

Owing to significantly growing prevalence of benign prostatic hyperplasia in North American men, benign prostatic hyperplasia prostate treatment market is expected to witness strong growth within the region, followed by Europe.

Extensive availability of benign prostatic hyperplasia prostate treatments, increasing clinical trials, improving R&D scenario, higher healthcare spending, and favorable government initiatives will continue to assist the growth of the benign prostatic hyperplasia prostate treatment market in developed regions.

On the other side, Asia Pacific’s benign prostatic hyperplasia prostate treatment market is foreseen to witness significant growth, owing to steadily expanding patient pool due in the region.

Preview Analysis Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Segmented By Treatment Type (drugs(alpha-blockers, alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs), devices (prostatic stents, suture base implant systems, and transurethral RF thermal therapy)); By Distribution Channel (Institutional sales (hospitals, ambulatory surgical centers, and specialty clinics), retail sales (retail pharmacies and drug stores), and online pharmacies) : https://www.futuremarketinsights.com/reports/benign-prostatic-hyperplasia-bph-and-prostate-treatment-market

UroLift System to Revolutionize the Competitive Landscape of Benign Prostatic Hyperplasia Prostate Treatment Market

Teleflex Incorporated’s NeoTract recently launched UroLift® System as a highly effective, least invasive option for benign prostatic hyperplasia prostate treatment. The UroLift® System is permanently implanted via a transurethral outpatient procedure and predominantly relieves prostate obstruction, which is one of the primary symptoms of benign prostatic hyperplasia. The company has also declared insurance coverage for UroLift® System. While the coverage is being provided by Humana, it is most likely to improve awareness about increasing availability and broadening access of minimally invasive treatment methods in urological conditions such as benign prostatic hyperplasia. This in turn will encourage adoption of UroLift® System among patients seeking effective benign prostatic hyperplasia prostate treatment.